dj
failur
penicillin
erad
group
b
streptococc
colon
pregnant
woman
coupl
studi
j
obstet
gynecol
yow
md
mason
eo
leed
lj
thompson
pk
clark
dj
gardner
se
ampicillin
prevent
intrapartum
transmiss
group
b
streptococcu
new
viru
emerg
healthcar
system
face
major
challeng
least
decid
treatment
use
drug
develop
process
novel
compound
screen
fi
nal
approv
take
year
complet
cost
hundr
million
dollar
contrast
virus
emerg
rapidli
spread
wide
pose
substanti
immedi
threat
public
health
exampl
middl
east
respiratori
syndrom
coronaviru
merscov
fi
rst
report
novemb
septemb
case
report
countri
confi
rmed
case
death
approv
drug
repurpos
use
variou
viral
infect
shorten
time
taken
viru
emerg
treatment
avail
other
screen
librari
drug
antimerscov
activ
vitro
howev
absenc
patholog
small
anim
model
make
screen
mani
drug
vivo
challeng
major
benefi
screen
preapprov
drug
drug
requir
undergo
extens
safeti
test
use
human
be
sinc
alreadi
deem
safe
human
use
lancet
infecti
diseas
ali
omrani
colleagu
report
result
retrospect
cohort
studi
use
preapprov
drug
ribavirin
interferon
treatment
merscov
ribavirin
synthet
analogu
ribonucleosid
guanosin
ribavirin
contain
carboxamid
group
guanin
nucleotid
allow
ribavirin
incorpor
rna
place
either
adenosin
guanosin
pair
equal
well
uracil
cytosin
therefor
ribavirin
thought
introduc
hypermut
rna
replic
product
random
incorpor
uracil
cytosin
ribavirin
shown
effi
caci
treatment
respiratori
syncyti
viru
haemorrhag
fever
viruseseg
hantaviru
lassa
fever
viru
interferon
type
interferon
innat
immun
cytokin
involv
antivir
innat
immun
respons
type
interferon
identifi
ed
potenti
treatment
rang
virus
pegyl
interferon
use
combin
ribavirin
treat
hepat
c
viru
infect
omrani
colleagu
present
data
fi
rst
clinic
use
ribavirin
pegyl
interferon
patient
merscov
show
treatment
ribavirin
pegyl
interferon
signifi
cantli
improv
surviv
day
diagnosi
merscov
infect
note
enhanc
surviv
day
diagnosi
patient
receiv
ribavirin
pegyl
interferon
enhanc
surviv
statist
signifi
cant
investig
acknowledg
sampl
size
studi
small
patient
receiv
treatment
control
patient
small
sampl
might
aff
ect
statist
complex
popul
therefor
data
day
diagnosi
valu
guidelin
might
statist
signifi
cant
larger
sampl
patient
despit
small
number
patient
studi
largest
clinic
test
ribavirin
interferon
combin
therapi
previou
studi
present
fi
two
patient
studi
take
advantag
rel
larg
number
patient
merscov
treat
princ
sultan
militari
medic
citi
saudi
arabia
make
import
initi
observ
use
ribavirin
pegyl
interferon
combin
therapi
outbreak
situat
time
treatment
crucial
number
patient
need
undertak
largescal
clinic
trial
might
small
pathogen
still
rare
contrast
initi
stage
outbreak
often
import
stop
spread
pathogen
therefor
smaller
studi
import
role
guid
futur
clinic
trial
diarrhoea
one
lead
killer
children
develop
countri
worldwid
rotaviru
identifi
ed
common
caus
sever
diarrhoea
children
younger
year
respons
hospit
admiss
death
everi
year
rotaviru
death
occur
lowincom
countri
asia
africa
india
nigeria
pakistan
democrat
republ
congo
ethiopia
account
global
death
countri
mortal
rate
exceed
per
children
africa
although
improv
hygien
sanit
coupl
provis
safe
drink
water
help
reduc
diarrhoeal
diseas
approach
inadequ
prevent
spread
rotavirus
effi
caci
two
avail
rotaviru
vaccinesrotarix
glaxosmithklin
biolog
rixensart
belgium
rotateq
merck
vaccin
whitehous
station
nj
usa
lower
prelicensur
trial
africa
asia
report
highincom
countri
europ
asia
howev
larg
diseas
burden
anticip
bigger
eff
ect
public
health
recommend
inclus
vaccin
nation
immunis
programm
especi
countri
high
child
mortal
caus
diarrhoea
far
countri
worldwid
incorpor
rotaviru
vaccin
immunis
programm
countri
africa
introduc
vaccin
expand
programm
immun
epi
support
gavi
allianc
acceler
vaccin
initi
howev
gavi
fund
period
complet
countri
pay
full
cost
vaccin
sustain
rotaviru
vaccin
might
ceas
prioriti
face
competit
need
resourc
alloc
nation
budget
therefor
crucial
understand
popul
eff
ect
routin
rotaviru
vaccin
countri
africa
includ
potenti
indirect
benefi
ts
vaccin
especi
sever
outcom
death
rotaviru
allcaus
diarrhoea
document
save
healthcar
cost
vaccin
michel
groom
colleagu
studi
eff
ectiv
monoval
human
rotaviru
vaccin
admiss
hospit
acut
rotaviru
diarrhoea
south
african
children
lancet
infecti
diseas
provid
fi
rst
evidencebas
data
africa
region
high
rotaviru
diseas
burden
assess
eff
ectiv
sustain
rotaviru
vaccin
africa
measur
vaccin
eff
ectiv
